We have proven that either systemically or topically applied Hsp90 inhibitors belonging to the geldanamycin derivatives (i.e., 17-DMAG or 17AAG) or short peptide derivative TCBL-145 ameliorated disease activity in experimental mouse models of EBA. Here, HSP90AB1 is linked to acquired epidermolysis bullosa.